{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T11:05:46Z","timestamp":1774436746513,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Pfizer Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s40744-023-00631-4","type":"journal-article","created":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T14:02:31Z","timestamp":1705932151000},"page":"313-329","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis\/Spondyloarthritis Registry"],"prefix":"10.1007","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct05195814","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J.","family":"Mease","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Fallon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajiv","family":"Mundayat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oluwaseyi","family":"Dina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taylor","family":"Blachley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Middaugh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis","family":"Ogdie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,22]]},"reference":[{"key":"631_CR1","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376:957\u201370.","journal-title":"N Engl J Med"},{"key":"631_CR2","first-page":"ii14","volume":"64","author":"DD Gladman","year":"2005","unstructured":"Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64:ii14\u20137.","journal-title":"Ann Rheum Dis"},{"key":"631_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/art.40726","volume":"71","author":"JA Singh","year":"2019","unstructured":"Singh JA, Guyatt G, Ogdie A, et al. Special article: 2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rhematol. 2019;71:5\u201332.","journal-title":"Arthritis Rhematol"},{"key":"631_CR4","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79:700\u201312.","journal-title":"Ann Rheum Dis"},{"key":"631_CR5","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18:465\u201379.","journal-title":"Nat Rev Rheumatol"},{"key":"631_CR6","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","volume":"377","author":"P Mease","year":"2017","unstructured":"Mease P, Hall S, FitzGerald O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017;377:1537\u201350.","journal-title":"N Engl J Med"},{"key":"631_CR7","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","volume":"377","author":"D Gladman","year":"2017","unstructured":"Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017;377:1525\u201336.","journal-title":"N Engl J Med"},{"key":"631_CR8","doi-asserted-by":"publisher","first-page":"E28","DOI":"10.1016\/S2665-9913(20)30339-8","volume":"3","author":"P Nash","year":"2020","unstructured":"Nash P, Mease PJ, Fleishaker D, et al. Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled sub-study of OPAL Balance. Lancet Rheumatol. 2020;3:E28-39.","journal-title":"Lancet Rheumatol"},{"key":"631_CR9","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","volume":"35","author":"L Blonde","year":"2018","unstructured":"Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018;35:1763\u201374.","journal-title":"Adv Ther"},{"key":"631_CR10","doi-asserted-by":"publisher","first-page":"vii54","DOI":"10.1093\/rheumatology\/key109","volume":"57","author":"S Monti","year":"2018","unstructured":"Monti S, Grosso V, Todoerti M, Caporali R. Randomized controlled trials and real-world data: differences and similarities to untangle literature data. Rheumatology. 2018;57:vii54\u20138.","journal-title":"Rheumatology"},{"key":"631_CR11","first-page":"206","volume":"28","author":"MJ Murage","year":"2022","unstructured":"Murage MJ, Princic N, Park J, et al. Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs. J Manag Care Spec Pharm. 2022;28:206\u201317.","journal-title":"J Manag Care Spec Pharm"},{"key":"631_CR12","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1007\/s12325-021-01687-w","volume":"38","author":"JA Walsh","year":"2021","unstructured":"Walsh JA, Cai Q, Lin I, Pericone CD, Chakravarty SD. Treatment persistence and adherence among patients with psoriatic arthritis who initiated targeted immune modulators in the US: a retrospective cohort study. Adv Ther. 2021;38:2353\u201364.","journal-title":"Adv Ther"},{"key":"631_CR13","doi-asserted-by":"publisher","first-page":"700","DOI":"10.3899\/jrheum.211033","volume":"49","author":"PJ Mease","year":"2022","unstructured":"Mease PJ, Blachley T, Dube B, et al. Effectiveness of 6-month use of secukinumab in patients with psoriatic arthritis in the CorEvitas Psoriatic Arthritis\/Spondyloarthritis Registry. J Rheumatol. 2022;49:700\u20136.","journal-title":"J Rheumatol"},{"key":"631_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000880","volume":"5","author":"PJ Mease","year":"2019","unstructured":"Mease PJ, Karki C, Liu M, et al. Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry. RMD Open. 2019;5: e000880.","journal-title":"RMD Open"},{"issue":"Suppl 9","key":"631_CR15","first-page":"1397","volume":"74","author":"A Ogdie","year":"2022","unstructured":"Ogdie A, O\u2019Brien J, Malley W, et al. Effectiveness by disease severity in patients with psoriatic arthritis treated with apremilast in the CorEvitas Psoriatic Arthritis\/Spondyloarthritis (PsA\/SpA) Registry. Arthrit Rheumatol. 2022;74(Suppl 9):1397\u20139.","journal-title":"Arthrit Rheumatol."},{"key":"631_CR16","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.1007\/s12325-022-02084-7","volume":"39","author":"PJ Mease","year":"2022","unstructured":"Mease PJ, Young P, Gruben D, Fallon L, Germino R, Kavanaugh A. Early real-world experience of tofacitinib for psoriatic arthritis: data from a United States Healthcare Claims Database. Adv Ther. 2022;39:2932\u201345.","journal-title":"Adv Ther"},{"key":"631_CR17","unstructured":"CorEvitas. Psoriatic Arthritis\/Spondyloarthritis Registry. 2022. https:\/\/www.corevitas.com\/registry\/psa-spa. Accessed 31 Nov 2022."},{"key":"631_CR18","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4:353\u201365.","journal-title":"Pharmacoeconomics"},{"key":"631_CR19","unstructured":"Reilly Associates. Work Productivity and Activity Questionnaire: Specific Health Problem V2.0 (WPAI:SHP). 2010. http:\/\/www.reillyassociates.net\/WPAI_SHP.html. Accessed 31 Oct 2022."},{"key":"631_CR20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1515\/sjpain-2019-0054","volume":"20","author":"F Wolfe","year":"2019","unstructured":"Wolfe F, Butler SH, Fitzcharles M, et al. Revised chronic widespread pain criteria: development from and integration with fibromyalgia criteria. Scand J Pain. 2019;20:77\u201386.","journal-title":"Scand J Pain"},{"key":"631_CR21","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s13075-018-1739-0","volume":"20","author":"P Helliwell","year":"2018","unstructured":"Helliwell P, Coates LC, FitzGerald O, et al. Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease. Arthritis Res Ther. 2018;20:242.","journal-title":"Arthritis Res Ther"},{"key":"631_CR22","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40744-018-0131-5","volume":"5","author":"P Nash","year":"2018","unstructured":"Nash P, Coates LC, Fleischmann R, et al. Efficacy of tofacitinib for the treatment of psoriatic arthritis: pooled analysis of two Phase 3 studies. Rheumatol Ther. 2018;5:567\u201382.","journal-title":"Rheumatol Ther"},{"key":"631_CR23","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s12325-021-02016-x","volume":"39","author":"K de Vlam","year":"2022","unstructured":"de Vlam K, Toukap AN, Kaiser MJ, et al. Real-world efficacy and safety of apremilast in Belgian patients with psoriatic arthritis: results from the prospective observational APOLO study. Adv Ther. 2022;39:1055\u201367.","journal-title":"Adv Ther"},{"key":"631_CR24","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.3899\/jrheum.110546","volume":"38","author":"PJ Mease","year":"2011","unstructured":"Mease PJ, Woolley JM, Bitman B, Wang BC, Globe DR, Singh A. Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction. J Rheumatol. 2011;38:2461\u20135.","journal-title":"J Rheumatol"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-023-00631-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-023-00631-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-023-00631-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T18:33:25Z","timestamp":1709836405000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-023-00631-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,22]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["631"],"URL":"https:\/\/doi.org\/10.1007\/s40744-023-00631-4","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,22]]},"assertion":[{"value":"3 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Philip J. Mease has acted as a consultant for and\/or has received grant\/research support from AbbVie, Acelyrin, Aclaris, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, CorEvitas, LLC, Eli Lilly, Galapagos, Gilead Sciences, Inmagene, Janssen, MoonLake, Novartis, Pfizer Inc, Sun, and UCB. Pamela Young, Lara Fallon, Rajiv Mundayat, and Oluwaseyi Dina are employees and stockholders of Pfizer\u00a0Inc. Taylor Blachley and Nicole Middaugh are employees of CorEvitas, LLC. Alexis Ogdie is a stockholder of Amgen, Novartis, and Pfizer Inc, and has received grant\/research support from AbbVie, Amgen, Bristol Myers Squibb, Celgene, CorEvitas, LLC, Eli Lilly, Novartis, and Pfizer Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was performed in accordance with Good Pharmacoepidemiology Practice. All participating investigators were required to obtain full board approval for conducting research involving human patients with a limited dataset. Sponsor approval and continuing review were obtained through a central Institutional Review Board (IRB), the New England Independent Review Board (No. 120160939). For academic investigative sites that did not receive a waiver to use the central IRB, full board approval was obtained from the respective governing IRBs and documentation of approval was submitted to CorEvitas, LLC, prior to the initiation of any study procedures. All patients in the registry were required to provide written informed consent and authorization prior to participating in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}